Histological and molecular evaluation of patient-derived colorectal cancer explants

Joshua M Uronis1, Takuya Osada, Shannon McCall

  • 1Institute for Genome Sciences and Policy, Duke University, Durham, North Carolina, United States of America.

Plos One
|June 8, 2012
PubMed

Insights

Patient-derived colorectal cancer explants (PDCCEs) in mice retain key tumor features. This suggests PDCCEs are a reliable preclinical model for developing personalized colorectal cancer therapies.

Area of Science:

  • Oncology
  • Translational Research
  • Preclinical Modeling

Background:

  • Mouse models are crucial for colorectal cancer research.
  • Tumor xenografts are standard for evaluating new cancer treatments.
  • The fidelity of explanted tumor tissues over time is not well understood.

Purpose of the Study:

  • To assess the reliability of patient-derived colorectal cancer explants (PDCCEs) as preclinical models.
  • To compare PDCCEs with original patient tumors for key pathological features.

Main Methods:

  • Generated 27 patient-derived colorectal cancer explants (PDCCEs) by transplanting human tumors into NOD-SCID mice.
  • Compared histology, gene expression, and mutation status between PDCCEs and original patient tissues.
  • Evaluated feature retention across multiple passages.

Main Results:

  • PDCCEs successfully maintained key histological features.
  • Basic gene expression patterns were preserved in PDCCEs.
  • KRAS/BRAF mutation status remained consistent through multiple passages.

Conclusions:

  • Patient-derived colorectal cancer explants (PDCCEs) closely resemble the original patient tumors.
  • PDCCEs show potential as a reliable preclinical model for colorectal cancer.
  • PDCCEs may aid in optimizing individualized colorectal cancer therapies.

Related Concept Videos